THOMAS C PEARSON, MD
Radiology in Atlanta, GA
License number
Georgia 026011
Category
Radiology
Type
Transplant Surgery
License number
Georgia 026011
Category
Radiology
Type
Pediatric Surgery
Address
Address
101 Wmb STE 5105, Atlanta, GA 30322
Phone
(404) 727-8464
(404) 727-3660 (Fax)
(404) 727-3660 (Fax)
Personal information
See more information about THOMAS C PEARSON at radaris.comName
Address
Phone
4480 Windsor Oaks Cir, Marietta, GA 30066
523 Fleming Rd, Luthersville, GA 30251
5403 Somer Mill Rd, Douglasville, GA 30134
3401 Bankhead Hwy, Douglasville, GA 30134
Professional information
Dr. Thomas C Pearson, Atlanta GA - MD (Doctor of Medicine)
Specialties:
General Surgery
Address:
101 Woodruff Cir, Atlanta 30322
(404) 727-8464 (Phone), (404) 727-3660 (Fax)
Emory University Hsp Outptnt TRA Clinic
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 712-5676 (Phone)
(404) 727-8464 (Phone), (404) 727-3660 (Fax)
Emory University Hsp Outptnt TRA Clinic
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 712-5676 (Phone)
Procedures:
Biopsy of Breast, Incisional/Ventral Hernia Repair, Open, Pancreatectomy (incl. Pancreas Transplant & Whipple Procedure), Port Placements or Replacements, Renal Transplant and Nephrectomy, Tracheal Surgery
Conditions:
Biliary Atresia, Breast Lump/Mass, Cholecystitis and Gallstones, Crohn's Disease (Regional Enteritis), Diaphragmatic/Hiatal Hernia, Hyperparathyroidism, Incisional Hernia, Inguinal Hernia, Intestinal Obstruction, Lipomas, Peripheral Arterial Embolism and Thrombosis, Peripheral Vascular Disease (PAD, PVD), Umbilical Hernia, Ventral Hernia
Certifications:
General Surgery, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
101 Woodruff Cir, Atlanta 30322
Emory University Hsp Outptnt TRA Clinic
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
Piedmont Hospital
1968 Peachtree Rd North #West, Atlanta 30309
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Emory University Hsp Outptnt TRA Clinic
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
Piedmont Hospital
1968 Peachtree Rd North #West, Atlanta 30309
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Education:
Medical School
Emory University School Of Medicine
Graduated: 1982
Emory University
Fell Emory University
Graduated: 1985
Oxford University
Emory University School Of Medicine
Graduated: 1982
Emory University
Fell Emory University
Graduated: 1985
Oxford University
Thomas Conrad Pearson, Atlanta GA
Specialties:
Surgery, Pediatric Surgery, Transplant Surgery
Work:
Emory University
101 Woodruff Cir, Atlanta, GA 30322 Emory University Hospital - Transplant Immunology
1365 Clifton Rd Ne, Atlanta, GA 30322 The Emory Clin
Emory University Transplantation Immunology, Atlanta, GA 30322 Emory University Transplantation Immunology
1639 Pierce Dr, Atlanta, GA 30322 Emory Hosp.
1364 Clifton Rd Ne, Atlanta, GA 30322
101 Woodruff Cir, Atlanta, GA 30322 Emory University Hospital - Transplant Immunology
1365 Clifton Rd Ne, Atlanta, GA 30322 The Emory Clin
Emory University Transplantation Immunology, Atlanta, GA 30322 Emory University Transplantation Immunology
1639 Pierce Dr, Atlanta, GA 30322 Emory Hosp.
1364 Clifton Rd Ne, Atlanta, GA 30322
Education:
Emory University(1982)
Dr. Thomas C Pearson, Springfield MO - MD (Doctor of Medicine)
Specialties:
Urology
Address:
Urology Group
3850 S National Ave SUITE 320, Springfield 65807
(417) 269-6944 (Phone)
3850 S National Ave SUITE 320, Springfield 65807
(417) 269-6944 (Phone)
Certifications:
Urology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Urology Group
3850 S National Ave SUITE 320, Springfield 65807
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
3850 S National Ave SUITE 320, Springfield 65807
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Education:
Medical School
University of Kansas / School of Medicine
Graduated: 1985
University Ky
Graduated: 1986
Graduated: 1990
University of Kansas / School of Medicine
Graduated: 1985
University Ky
Graduated: 1986
Graduated: 1990
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
2002003, Mar 14, 2002
Filed:
May 22, 2001
Appl. No.:
09/862255
Inventors:
Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
Assignee:
Bristol-Myers Squibb Company
International Classification:
A61K039/395
US Classification:
424/131100, 424/144100
Abstract:
The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
2009018, Jul 23, 2009
Filed:
Sep 10, 2008
Appl. No.:
12/207997
Inventors:
Christian P. Larsen - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US
International Classification:
A61K 39/395, A61K 38/16, A61P 37/06
US Classification:
4241441, 514 12
Abstract:
The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
5916560, Jun 29, 1999
Filed:
Mar 20, 1997
Appl. No.:
8/821400
Inventors:
Christian P. Larsen - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA
Assignee:
Bristol-Myers Squibb Company - Pinceton NJ
Emory University - Atlanta GA
Emory University - Atlanta GA
International Classification:
C07K 1628
US Classification:
4241541
Abstract:
The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
2005020, Sep 15, 2005
Filed:
Jan 4, 2005
Appl. No.:
11/028793
Inventors:
Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Edmonds WA, US
Diane Hollenbaugh - Seattle WA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
Alejandro Aruffo - Edmonds WA, US
Diane Hollenbaugh - Seattle WA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
International Classification:
A61K039/395
US Classification:
424144100
Abstract:
The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules
US Patent:
7829534, Nov 9, 2010
Filed:
Oct 29, 2007
Appl. No.:
11/978701
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16, C07K 14/705, C07K 16/46
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules
US Patent:
7304033, Dec 4, 2007
Filed:
May 23, 2002
Appl. No.:
10/155514
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16, C07K 14/00
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.
Methods Of Inducing Organ Transplant Tolerance And Correcting Hemoglobinopathies
US Patent:
2003000, Jan 9, 2003
Filed:
Jan 25, 2002
Appl. No.:
10/057288
Inventors:
Christian Larsen - Atlanta GA, US
Thomas Pearson - Atlanta GA, US
Edmund Waller - Atlanta GA, US
Andrew Adams - Atlanta GA, US
Thomas Pearson - Atlanta GA, US
Edmund Waller - Atlanta GA, US
Andrew Adams - Atlanta GA, US
International Classification:
A61K039/395, A61K031/255, A61K045/00
US Classification:
424/144100, 424/093700, 514/517000
Abstract:
Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell depleted bone marrow cells.